Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12349909 | 0.88 | MAPK1 (0.47) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25896876 | 0.83 | MAPT (0.54) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9525229 | 0.83 | MAPT (0.54) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16376052 | 0.83 | MEN1 (0.43) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9348606 | 0.81 | MAPT (0.56) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5301321 | 0.81 | SMN1; SMN2 (0.40) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12932855 | 0.80 | MAPK1 (0.51) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12963097 | 0.80 | G6PD (0.59) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2674642 | 0.77 | MEN1 (0.53) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1966606 | 0.77 | SMN1; SMN2 (0.49) | MAPTMAPK1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007016190-A2 | ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES | DUKE UNIVERSITY (US) | 2007-02-08 | — | — | WO | claimed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | claimed |
| US-20220388968-A1 | INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2022-12-08 | — | — | US | disclosed |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | UNIVERSITY OF PUERTO RICO (US) | 2020-08-04 | — | — | US | disclosed |
| CN-109627193-B | Diaryl azo oxygen compound with anti-tumor effect and synthesis method thereof | 华中科技大学 | 2020-05-22 | — | — | CN | disclosed |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | UNIVERSITY OF PUERTO RICO (PR) | 2019-05-02 | — | — | US | disclosed |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | ARRAY BIOPHARMA INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA INC. | 2018-05-10 | — | — | US | disclosed |
| US-20170114067-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | UNIV DUKE (US) | 2015-01-22 | — | — | US | disclosed |
| US-8877802-B2 | Antiparkinsonian action of phenylisopropylamines | Duke Univerity (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110281908-A1 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2011-11-17 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027208-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | MAPT 393/4885MAPK1 3527/4885MEN1 3929/4885 |
| US-20180127427-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MAPT 1009/4885MAPK1 1475/4885MEN1 4187/4885 |
| US-10005783-B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | TYMP, TYMS, P2RX7 | MAPT 1009/4885MAPK1 1475/4885MEN1 4187/4885 |
| US-20170114067-A1 | METHOD OF TREATMENT USING SUBSTITUTED PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS | TYMP, TYMS, P2RX7 | MAPT 1009/4885MAPK1 1475/4885MEN1 4187/4885 |
| US-20150025063-A1 | Antiparkinsonian Action of Phenylisopropylamines | PNMT, SNCA, COMT | MAPT 393/4885MAPK1 3527/4885MEN1 3929/4885 |
| US-20220388968-A1 | INHIBITORS OF ERYTHROCYTE BAND 3 TYROSINE PHOSPHORYLATION AND USES THEREOF | SPTBN1, CTTN, HBG1 | MAPT 2296/4885MAPK1 614/4885MEN1 4567/4885 |
| US-20190125746-A1 | NOVEL CARBAZOLE EHOP-016 DERIVATIVES AS ANTI-CANCER AND ANTI-MIGRATORY AGENTS | CDC42, ARHGEF2, HRAS | MAPT 3896/4885MAPK1 482/4885MEN1 2021/4885 |
| US-10729689-B2 | Carbazole EHop-016 derivatives as anti-cancer and anti-migratory agents | CDC42, ARHGEF2, GDI2 | MAPT 3908/4885MAPK1 393/4885MEN1 1556/4885 |
| US-20110281908-A1 | Aminoquinoline Derived Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AB2P, HSP90AA1 | MAPT 142/4885MAPK1 1216/4885MEN1 4399/4885 |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 357/4885MAPK1 1058/4885MEN1 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.